medication error due to temperature excursion exceeded the stability data, with no reported adverse event; TUBERSOL was potentially administered to a patient after it was not suitable to use post excursion, with no reported adverse event; Initial information received on 23-Jun-2022 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a patient (unknown age and gender) who experienced medication error due to temperature excursion exceeded the stability data, with no reported adverse event and tubersol was potentially administered to a patient after it was not suitable to use post excursion, with no reported adverse event while receiving vaccines yellow fever vaccine - us, diphtheria-2/tetanus/5 ac pertussis vaccine [adacel], diphtheria-2/tetanus-5 adsorbed toxoids no preservative adult [tenivac], typhoid vi polysaccharide vaccine [typhim vi], meningococcal a-c-y-w135 (d conj) vaccine [menactra], diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine [pentacel] and ipv (vero) [ipol], tuberculin test [tubersol] and influenza quadrival A-B high dose hv vaccine [fluzone high-dose quadrivalent].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  on an unknown date, the patient started taking l tuberculin test solution for injection (strength, dose, formulation, route: unknown) (lot - c5840aa), suspect ipv (vero) (strength, dose, formulation, route, lot number and expiry date: unknown), suspect diphtheria/tetanus/5 hybrid ac pertussis/IPV(MRC5)/HIB(PRP/T) vaccine (strength, dose, formulation, route, lot number and expiry date: unknown), suspect meningococcal a-c-y-w135 (d conj) vaccine (strength, dose, formulation, route, lot number and expiry date: unknown), suspect typhoid vi polysaccharide vaccine (strength, dose, formulation, route, lot number and expiry date: unknown), suspect diphtheria-2/tetanus-5 adsorbed toxoids no preservative adult (strength, dose, formulation, route, lot number and expiry date: unknown), suspect diphtheria-2/tetanus/5 ac pertussis vaccine (strength, dose, formulation, route, lot number and expiry date: unknown), yellow fever vaccine - us (strength, dose, formulation, route, lot number and expiry date: unknown) and influenza quadrival a-b high dose hv vaccine all for prophylactic vaccination.  On an unknown date the patient developed a non-serious medication error due to temperature excursion exceeded the stability data, with no reported adverse event (product temperature excursion issue) and tubersol was potentially administered to a patient after it was not suitable to use post excursion, with no reported adverse event (Product use issue) (unknown latency) following while receiving vaccines yellow fever vaccine - us [yf-vax], diphtheria-2/tetanus/5 ac pertussis vaccine [adacel], diphtheria-2/tetanus-5 adsorbed toxoids no preservative adult [tenivac], typhoid vi polysaccharide vaccine [typhim vi], meningococcal a-c-y-w135 (d conj) vaccine [menactra], diphtheria/tetanus/5 hybrid ac pertussis/ipv(mrc5)/hib(prp/t) vaccine and ipv (vero), tuberculin test [tubersol] and influenza quadrival A-B high dose hv vaccine.  Action taken: Not applicable.  It was not reported if the patient received a corrective treatment for the events.  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.